Higher patient adherence to DMDs reduces MS costs
Higher patient adherence to DMDs reduces MS costs
Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.
This research was published in the December issue of the Journal of Medical Economics....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 23 Replies
- 3355 Views
-
Last post by vesta
-
- 0 Replies
- 1711 Views
-
Last post by NHE
-
- 0 Replies
- 1681 Views
-
Last post by NHE
-
- 0 Replies
- 1172 Views
-
Last post by frodo
-
- 0 Replies
- 655 Views
-
Last post by frodo
-
- 0 Replies
- 1348 Views
-
Last post by NHE
-
- 0 Replies
- 2515 Views
-
Last post by NHE
-
- 3 Replies
- 4860 Views
-
Last post by NHE